Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity. Does it make sense?

Arch Otolaryngol Head Neck Surg. 1994 Sep;120(9):934-9. doi: 10.1001/archotol.1994.01880330022005.

Abstract

Objective: To evaluate whether additional curative treatment was possible in patients for whom routine long-term follow-up had led to the early detection of locoregional recurrence, distant metastases, and second primary tumors (events).

Design: Cohort study with a maximum follow-up of 126 months and a consensus questionnaire.

Setting: Department of Head and Neck Oncology at the University Hospital Nijmegen (the Netherlands).

Patients: There were 428 patients treated with curative intent for carcinoma of the larynx, pharynx, and oral cavity from 1979 to 1983.

Main outcome measures: Site, stage, differentiation grade, and type of treatment of index tumor (routine follow-up vs self-referral).

Results: There were 205 patients (47.9%) who developed events, 76.1% within 3 years of initial treatment. Eighty-nine patients (43.4%) received curative treatment. The detection rate for events during routine follow-up (6350 appointments) was one in 34, and for self-referrals (54) it was one in 2.7; the cure rates were one in 78 and one in 6.8, respectively. The mean survival after detection of events with routine follow-up was significantly (P < .05) better than with self-referral (58 vs 32 months, respectively).

Conclusions: Routine follow-up is indispensible. Site and stage of the index tumor played a part in the length of routine follow-up, in contrast to the differentiation grade or type of initial treatment. Yearly chest roentgenograms were valuable only for laryngeal index tumors. Patients considered routine follow-up important; however, negative findings at physical examination of complaints did not reassure all patients.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Squamous Cell / secondary
  • Carcinoma, Squamous Cell / therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Laryngeal Neoplasms / therapy*
  • Male
  • Middle Aged
  • Mouth Neoplasms / therapy*
  • Neoplasm Metastasis / diagnosis
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasms, Second Primary / diagnosis*
  • Patient Satisfaction
  • Pharyngeal Neoplasms / therapy*
  • Retrospective Studies
  • Surveys and Questionnaires
  • Survival Rate